We are excited to share a recent publication from our own Professor Sanderson, describing results of Anti-MAP Antibiotic Therapy prescribed for 24 months (median) to Crohn’s patients at Guy’s and St Thomas’s Hospital and London Bridge Hospital.
The treatment was well tolerated and a response was seen in 46% of patients studied.
This published evidence strongly supports the outcome of last year’s MAPUS phase 3 RCT via Redhill Biopharma, which achieved similar results.